Today: 29 January 2026
Subscribe
Browse Category

NASDAQ:SLNO News 30 December 2025 - 9 January 2026

Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny

Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny

New York, Jan 9, 2026, 13:28 (EST) — Regular session Soleno Therapeutics shares slid on Friday, extending a choppy stretch for the rare-disease drugmaker. The stock was down 5.6% at $42.95, after touching a low of $42.73, while the SPDR S&P Biotech ETF was up about 1.1%. The move matters now because Soleno’s story still hinges on a young commercial…
9 January 2026
···
Soleno Therapeutics stock slides today: SLNO drops on investor-alert headline as biotech sector slips

Soleno Therapeutics stock slides today: SLNO drops on investor-alert headline as biotech sector slips

NEW YORK, December 30, 2025, 2:16 PM ET — Regular session Shares of Soleno Therapeutics, Inc. fell 3.1% to $46.09 in afternoon trading on Tuesday, after a law firm said it was investigating potential claims on behalf of investors. The drop outpaced declines in biotech benchmarks, with the SPDR S&P Biotech ETF down about 1.4% and the iShares Nasdaq Biotechnology…
30 December 2025
···

Stock Market Today

  • Foresight Group Holdings conducts share buyback purchasing 39,726 shares
    January 29, 2026, 2:16 AM EST. Foresight Group Holdings Limited announced a purchase of 39,726 ordinary shares on January 28, 2026, as part of its ongoing share buyback programme initiated in April 2025. The shares were acquired at prices ranging from 427 to 433 GBp, with a volume-weighted average price of 431.6 GBp. Post-transaction, the Group holds a total of 1,508,272 shares in treasury, which carry no voting rights. Overall, 3,159,956 ordinary shares have been repurchased under the programme. The buyback was executed through Berenberg on the London Stock Exchange. The total Ordinary Shares in issue stand at 116,347,803, with 114,839,531 carrying voting rights. This latest activity reflects Foresight's strategy to optimize its capital structure.
Go toTop